Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...

While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

One dose of a human papillomavirus (HPV) vaccine was noninferior to two doses in preventing infection, data from a randomized ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of $15.31 billion and $2.14, respectively.

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios. Read more on MRK and SLB stocks here.

Sales of Gardasil declined 40% due to lower demand in China, Merck maintained its sales guidance in the range of $64.1-$65.6 billion. Merck expects sales to accelerate in the second half of the year.

Let’s understand the company’s strengths and weaknesses to better analyze how to play MRK stock in the post-earnings scenario ...

Robert F. Kennedy Jr., the secretary of the Department of Health and Human Services, has long criticized HPV vaccines, particularly Gardasil, made by Merck, which is the HPV vaccine used in the U ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...